Department of Bioinspired Science and Laboratory of Medicinal Chemistry, College of Pharmacy, Ewha Womans University, Seoul 120-750, Korea.
J Org Chem. 2011 May 6;76(9):3557-61. doi: 10.1021/jo2001897. Epub 2011 Mar 21.
MLN4924 (1), which is in clinical trials as an anticancer agent, was stereoselectively synthesized from d-ribose via a route involving stereoselective reduction, regioselective cleavage of an isopropylidene moiety, and selective displacement of a cyclic sulfate moiety as key steps.
MLN4924(1)正在临床试验中作为一种抗癌药物,它是从 D-核糖通过一条路线立体选择性合成的,该路线涉及立体选择性还原、异丙叉部分的区域选择性裂解以及环状硫酸酯部分的选择性取代作为关键步骤。